168 related articles for article (PubMed ID: 19768519)
1. The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.
Watanabe S; Miyake K; Ogawa C; Matsumoto H; Yoshida K; Hirabayashi S; Hasegawa D; Inoue T; Kizu J; Machida R; Ohara A; Hosoya R; Manabe A
Int J Hematol; 2009 Oct; 90(3):347-352. PubMed ID: 19768519
[TBL] [Abstract][Full Text] [Related]
2. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia.
Czogała M; Balwierz W; Sztefko K; Rogatko I
Biomed Res Int; 2014; 2014():945860. PubMed ID: 25157375
[TBL] [Abstract][Full Text] [Related]
4. Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
Nakamura T; Oya S; Ozawa H; Maehiro Y; Muta S; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Naito Y; Nagafuji K
Int J Hematol; 2024 Apr; 119(4):426-431. PubMed ID: 38363480
[TBL] [Abstract][Full Text] [Related]
5. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
[TBL] [Abstract][Full Text] [Related]
7. [The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia].
Akazai A; Oda M; Nishiuchi R; Horiuchi T; Henmi M; Manki A; Seino Y
Rinsho Ketsueki; 1996 Feb; 37(2):95-100. PubMed ID: 8852025
[TBL] [Abstract][Full Text] [Related]
8. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
9. Ammonia Levels Should Not Be Used as a Surrogate Marker of Levels of Asparaginase Activity in Acute Lymphoblastic Leukemia Patients.
Tong WH; Pieters R; van der Sluis IM
Pediatr Blood Cancer; 2016 Mar; 63(3):564-5. PubMed ID: 26397054
[No Abstract] [Full Text] [Related]
10. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
[TBL] [Abstract][Full Text] [Related]
11. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
12. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Sandlund JT; Ribeiro RC; Rivera GK; Rubnitz JE; Harrison PL; Wang B; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2000 Apr; 18(7):1525-32. PubMed ID: 10735901
[TBL] [Abstract][Full Text] [Related]
13. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
Ylikangas P; Mononen I
Anal Biochem; 2000 Apr; 280(1):42-5. PubMed ID: 10805519
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin III as the Indicator of L-Asparaginase Activity in Children Treated for Acute Lymphoblastic Leukemia.
Czogała M; Balwierz W; Sztefko K; Rogatko I
J Pediatr Hematol Oncol; 2017 Mar; 39(2):114-120. PubMed ID: 28060110
[TBL] [Abstract][Full Text] [Related]
18. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
Salzer W; Bostrom B; Messinger Y; Perissinotti AJ; Marini B
Leuk Lymphoma; 2018 Aug; 59(8):1797-1806. PubMed ID: 29045165
[TBL] [Abstract][Full Text] [Related]
19. Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia.
Speas AL; Lyles SE; Wirth KA; Fahey CE; Kow K; Lejeune AT; Milner RJ
J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):130-139. PubMed ID: 29469204
[TBL] [Abstract][Full Text] [Related]
20. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
